Breast cancer research and treatment · 2026
Oncologic safety of prophylactic nipple-sparing mastectomy: Outcomes of 1,255 cases exceeding a 6-year median follow-up.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amburn Thomas, Parvin-Nejad Fatemeh P, Sevilimedu Varadan, Zou Huayue, Montagna Giacomo, Moo Tracy-Ann, El-Tamer Mahmoud, Morrow Monica, Sacchini Virgilio
Аннотация
BACKGROUND: Prophylactic nipple-sparing mastectomy (PNSM) is performed to prevent the development of breast cancer. Despite the increasing usage of PNSM, large-cohort, long-term follow-up data is lacking. We aim to review a large cohort of PNSM cases to evaluate oncologic outcomes.
METHODS: We retrospectively reviewed all PNSMs between 2000 and 2021 at a single institution. Clinicopathologic variables were collected and analyzed. Descriptive statistics and Kaplan Meier (KM) based survival analyses were used.
RESULTS: A total of 1,255 PNSMs in 972 patients were performed from 2000 to 2021 with a median age of 43 years (IQR 37, 49) and a median follow-up of 81.3 months (IQR 50.8, 123.0). There were 38 (3.0%) cases of incidental breast cancer discovered on surgical pathology. There were 3 (0.3%) new primary breast cancer occurrences after PNSM. The KM estimates for 5-year rates in the entire cohort (n = 972) of incidence of new breast cancer, breast cancer-related mortality, and overall mortality were as follows: 0.15% (95%CI 0, 0.44%), 0.93% (95%CI 0.28%, 1.57%), and 1.63% (95%CI 0.78%, 2.48%), respectively. The KM estimates for 5-year rates in the BRCA-only cohort (n = 333) of incidence of new breast cancer, breast cancer-related mortality, and overall mortality were as follows: 0.44% (95%CI 0, 1.30%), 1.75% (95%CI 0.21%, 3.26%), and 2.09% (95%CI 0.42%, 3.73%), respectively.
CONCLUSION: New primary breast cancer infrequently developed after PNSM in this study. Incidental breast cancer was identified on surgical pathology in a small subset of patients. PNSM may be associated with preventing breast cancer development.
METHODS: We retrospectively reviewed all PNSMs between 2000 and 2021 at a single institution. Clinicopathologic variables were collected and analyzed. Descriptive statistics and Kaplan Meier (KM) based survival analyses were used.
RESULTS: A total of 1,255 PNSMs in 972 patients were performed from 2000 to 2021 with a median age of 43 years (IQR 37, 49) and a median follow-up of 81.3 months (IQR 50.8, 123.0). There were 38 (3.0%) cases of incidental breast cancer discovered on surgical pathology. There were 3 (0.3%) new primary breast cancer occurrences after PNSM. The KM estimates for 5-year rates in the entire cohort (n = 972) of incidence of new breast cancer, breast cancer-related mortality, and overall mortality were as follows: 0.15% (95%CI 0, 0.44%), 0.93% (95%CI 0.28%, 1.57%), and 1.63% (95%CI 0.78%, 2.48%), respectively. The KM estimates for 5-year rates in the BRCA-only cohort (n = 333) of incidence of new breast cancer, breast cancer-related mortality, and overall mortality were as follows: 0.44% (95%CI 0, 1.30%), 1.75% (95%CI 0.21%, 3.26%), and 2.09% (95%CI 0.42%, 3.73%), respectively.
CONCLUSION: New primary breast cancer infrequently developed after PNSM in this study. Incidental breast cancer was identified on surgical pathology in a small subset of patients. PNSM may be associated with preventing breast cancer development.